FEFU scientists are developing genetic methods to understand malignant tumors

(Far Eastern Federal University) Scientists of Far Eastern Federal University (FEFU University) get started studying the formation and survival mechanisms of the brain malignant tumors cells, i.e. glioma, to reveal new ways for diagnosis and therapy for this fatal disease. This research was supported by the grant from Russian Science Foundation (RSF).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

High-grade gliomas (HGGs), including glioblastoma and diffuse intrinsic pontine glioma, are amongst the most fatal brain tumors. These tumors are associated with a dismal prognosis with a median survival of le...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Glioblastoma is a poorly immunogenic cancer, and the successes with recent immunotherapies in extracranial malignancies have, so far, not been translated to this devastating disease. Therefore, there is an urgent need for new strategies to convert the immunologically cold glioma microenvironment into a hot one to enable effective antitumor immunity. Using the L19 antibody, which is specific to a tumor-associated epitope of extracellular fibronectin, we developed antibody-cytokine fusions—immunocytokines—with interleukin-2 (IL2), IL12, or tumor necrosis factor (TNF). We showed that L19 accumulated in the tumor m...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
ConclusionsNovel nano-enhanced radiotherapy with gadolinium-containing nanoparticles is ideally suited for implementation on an MRI-linac, allowing a workflow with time-of-treatment imaging. Live irradiations using this treatment workflow, carried out for the first time at the Australian MRI-linac, confirm the safety and feasibility of performing MRI-guided radiotherapy with AGuIX® nanoparticles. Follow-up studies are needed to demonstrate on an MRI-linac the radiation enhancement effects previously shown with conventional radiotherapy.
Source: Cancer Nanotechnology - Category: Cancer & Oncology Source Type: research
miR‑181d promotes cell proliferation via the IGF1/PI3K/AKT axis in glioma. Mol Med Rep. 2020 Nov;22(5):3804-3812 Authors: Tang D, Gao W, Yang J, Liu J, Zhao J, Ge J, Chen Q, Liu B Abstract Glioma is a malignant brain cancer that exhibits high invasive ability and poor prognosis. MicroRNA (miR)‑181d has been reported to be involved in the development of glioma. Therefore, the aim of the present study was to investigate whether miR‑181d affected cellular progression by influencing the insulin like growth factor (IGF1)/PI3K/AKT axis. Western blot analysis was performed to analyze the expression leve...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Radiotherapy is an important therapeutic approach to treating malignant tumors of different localization, including brain cancer. Glioblastoma multiforme (GBM) represents the most aggressive brain tumor, which develops relapsed disease during the 1st year after the surgical removal of the primary node, in spite of active adjuvant radiochemotherapy. More and more evidence suggests that the treatment's success might be determined by the balance of expected antitumor effects of the treatment and its non-targeted side effects on the surrounding brain tissue. Radiation-induced damage of the GBM microenvironment might create tum...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
erlik Malignant gliomas (MG) are among the most prevalent and lethal primary intrinsic brain tumors. Although radiotherapy (RT) is the most effective nonsurgical therapy, recurrence is universal. Dysregulated DNA damage response pathway (DDR) signaling, rampant genomic instability, and radio-resistance are among the hallmarks of MGs, with current therapies only offering palliation. A subgroup of pediatric high-grade gliomas (pHGG) is characterized by H3K27M mutation, which drives global loss of di- and trimethylation of histone H3K27. Here, we review the most recent literature and discuss the key studies dissecting the...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Glioma is a deadly and immunosuppressive brain tumour. Complement C1r subcomponent like (C1RL), a prognostic biomarker in several kinds of tumours, has attracted increasing attention from oncologists. However, th...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
ConclusionsOur data revealed novel functional roles for miR-650 in glioma development and may provide new avenues for future clinical applications.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
ConclusionspcPET tracers present potential utility in the differential diagnosis, estimation of prognosis, evaluation of recurrence and treatment planning in patients with glioma. These radiotracers may hold a complementary role in conjunction with advanced MRI techniques in the non-invasive grading of gliomas.
Source: Clinical and Translational Imaging - Category: Radiology Source Type: research
Authors: Chen BS, Wang KY, Yu SQ, Zhang CB, Li GZ, Wang ZL, Bao ZS Abstract Gliomas are the most common type of primary brain tumor in adults with a high mortality rate. Low-grade gliomas progress to glioblastoma multiforme (GBM) in the majority of cases, forming secondary GBM (sGBM), followed by rapid fatal clinical outcomes. Protein tyrosine phosphatase receptor type Z1 (PTPRZ1)-MET proto-oncogene receptor tyrosine kinase (MET) (ZM) fusion has been identified as a biomarker for sGBM that is involved in glioma progression, but the mechanism of gliomagenesis and pathology of ZM-negative sGBM has remained to be full...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Genetics | Glioma | Grants | Neurology | Russia Health | Science